Journal Mobile Options
Table of Contents
Vol. 4, No. 3, 2011
Issue release date: September – December
Open Access Gateway
Case Rep Oncol 2011;4:452–457
(DOI:10.1159/000332044)

An Unusual Case of Locally Advanced Glycogen-Rich Clear Cell Carcinoma of the Breast

Martín-Martín B.a · Berná-Serna J.D.a · Sánchez-Henarejos P.b · López-Poveda M.J.c · Berná-Mestre J.D.a · Rodríguez-García J.R.d
Departments of aRadiology, bOncology, cPathology and dObstetrics and Gynecology, Virgen de la Arrixaca University Hospital, Murcia, Spain
email Corresponding Author

Abstract

Glycogen-rich clear cell (GRCC) is a rare subtype of breast carcinoma characterized by carcinoma cells containing an optically clear cytoplasm and intracytoplasmic glycogen. We present the case of a 55-year-old woman with a palpable mass in the right breast and clinical signs of locally advanced breast cancer (LABC). The diagnosis of GRCC carcinoma was based on certain histopathological characteristics of the tumor and immunohistochemical analysis. To our knowledge, this is the first case of GRCC LABC with intratumoral calcifications. There is no evidence of recurrence or metastatic disease after 14 months’ follow-up.


 Outline


 goto top of outline Key Words

  • Glycogen-rich clear cell carcinoma
  • Locally advanced breast cancer
  • Mammography
  • Ultrasonography

 goto top of outline Abstract

Glycogen-rich clear cell (GRCC) is a rare subtype of breast carcinoma characterized by carcinoma cells containing an optically clear cytoplasm and intracytoplasmic glycogen. We present the case of a 55-year-old woman with a palpable mass in the right breast and clinical signs of locally advanced breast cancer (LABC). The diagnosis of GRCC carcinoma was based on certain histopathological characteristics of the tumor and immunohistochemical analysis. To our knowledge, this is the first case of GRCC LABC with intratumoral calcifications. There is no evidence of recurrence or metastatic disease after 14 months’ follow-up.

Copyright © 2011 S. Karger AG, Basel


 goto top of outline Author Contacts

Dr. Juan de Dios Berná Serna
Department of Radiology Virgen de la Arrixaca University Hospital ES–30120 Murcia (Spain)
Tel. +34 968 369 596, E-Mail jdberna@gmail.com


 goto top of outline Article Information

Published online: September 7, 2011
Number of Print Pages : 6
Number of Figures : 4,


 goto top of outline Publication Details

Case Reports in Oncology

Vol. 4, No. 3, Year 2011 (Cover Date: September - December)

Journal Editor: Markman M. (Philadelphia, Pa.)
ISSN: NIL (Print), eISSN: 1662-6575 (Online)

For additional information: http://www.karger.com/CRO


Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Abstract

Glycogen-rich clear cell (GRCC) is a rare subtype of breast carcinoma characterized by carcinoma cells containing an optically clear cytoplasm and intracytoplasmic glycogen. We present the case of a 55-year-old woman with a palpable mass in the right breast and clinical signs of locally advanced breast cancer (LABC). The diagnosis of GRCC carcinoma was based on certain histopathological characteristics of the tumor and immunohistochemical analysis. To our knowledge, this is the first case of GRCC LABC with intratumoral calcifications. There is no evidence of recurrence or metastatic disease after 14 months’ follow-up.



 goto top of outline Author Contacts

Dr. Juan de Dios Berná Serna
Department of Radiology Virgen de la Arrixaca University Hospital ES–30120 Murcia (Spain)
Tel. +34 968 369 596, E-Mail jdberna@gmail.com


 goto top of outline Article Information

Published online: September 7, 2011
Number of Print Pages : 6
Number of Figures : 4,


 goto top of outline Publication Details

Case Reports in Oncology

Vol. 4, No. 3, Year 2011 (Cover Date: September - December)

Journal Editor: Markman M. (Philadelphia, Pa.)
ISSN: NIL (Print), eISSN: 1662-6575 (Online)

For additional information: http://www.karger.com/CRO


Open Access License / Drug Dosage

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.